Eiger BioPharmaceuticals, Inc.
EIGR
Clasificación en acciones
#36446
Eiger BioPharmaceuticals, Inc. is a commercial-stage biopharmaceutical company... Eiger BioPharmaceuticals, Inc. is a commercial-stage biopharmaceutical company dedicated to developing and bringing to market targeted therapies for rare and ultra-rare diseases across the United States and internationally. Its primary investigational drug, Lonafarnib, an orally administered small molecule, is currently undergoing Phase III clinical trials for the treatment of hepatitis delta virus (HDV) infection. Other promising candidates in its portfolio include Lambda, which has completed Phase II clinical trials and is designed to target type III interferon receptors; Lonafarnib, also being evaluated for progeria and progeroid laminopathies; and Avexitide, an agent for congenital hyperinsulinism that has also successfully concluded Phase II studies for post-bariatric hypoglycemia. Established in 2008, Eiger BioPharmaceuticals, Inc. maintains its headquarters in Palo Alto, California.
Precio por acción
$1.73
Última sincronización: 2025-06-17
Capitalización bursátil
$2.55M
Cambio (1 día)
-0.29%
Cambio (1 año)
-79.71%
País
US
Comercio Eiger BioPharmaceuticals, Inc. (EIGR)
Categoría
Healthcare
EPS de Eiger BioPharmaceuticals, Inc. (EIGR)
EPS a fecha de December 2023 TTM: $-50.79
Según los últimos informes financieros y el precio de las acciones de Eiger BioPharmaceuticals, Inc., el EPS actual de la empresa (TTM) es $-50.79. Al final del año 2022, la empresa tenía un EPS de $-69.74 un aumento con respecto a al EPS de 2021, que fue de $-29.98.
Historial de EPS de Eiger BioPharmaceuticals, Inc. desde 2016 hasta 2026
EPS al final de cada año
| Año | EPS | Cambiar |
|---|---|---|
| 2026 (TTM) | $-50.79 | 0.02% |
| 2023 | $-50.78 | -27.19% |
| 2022 | $-69.74 | 132.62% |
| 2021 | $-29.98 | -56.76% |
| 2020 | $-69.34 | -25.04% |
| 2019 | $-92.50 | -19.31% |
| 2018 | $-114.63 | -21.43% |
| 2017 | $-145.90 | -37.96% |
| 2016 | $-235.16 | 0.00% |
EPS de empresas similares o competidoras
| Empresa | EPS | Diferencia de EPS | País |
|---|---|---|---|
| $17.32 | -134.10% |
US
|
|
| $-7.98 | -84.29% |
US
|
|
| $-5.29 | -89.58% |
AU
|
|
| - | - |
CH
|
|
| $27.74 | -154.62% |
NL
|
